Seagen Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Seagen Inc (SGEN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Seagen Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2,300M vs 209,112M combined for its competitors (1.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+12.8% annualized vs trailing 12 months), vs decelerating (-44.5%) for its tracked peer group.
- Growth: Seagen Inc generated 27.1% revenue growth year over year in Q3 2023, vs -1.2% for its competitors combined.
- Profitability: Its -33.3% net margin compares with 15.2% for the peer group.
- Peer revenue share: Seagen Inc accounted for 2.2% of combined revenue among its tracked peer group, up from 1.7% a year earlier.
- Peer differentiation: Revenue per employee of $1.92M compares with $1.24M for the peer group (1.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SGEN Sales vs. its Competitors, Q3 2023
Seagen Inc reported revenue growth of 27.11 % year on year in Q3 2023, above its competitors' combined revenue change of -1.24 %.
With a net margin of -33.27 %, Seagen Inc reported lower profitability than its competitors (15.22 %).
Seagen Inc generated 2.19 % of the combined sales of its peer group, up from 1.71 % a year earlier.
API endpoints for this dataset
Seagen Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Seagen Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Seagen Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Seagen Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (128) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Seagen Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.4% year over year, combined, vs 27.1% for Seagen Inc. Seagen Inc's share of combined industry revenue moved from 1.36% to 1.43%, a gain of 0.06 percentage points.
Seagen Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Seagen Inc | No | Yes | Yes | Yes |
| Competitors combined (80) | ||||
| High-Confidence Competitors (138) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 100.00 % (8 of 8) | 62.50 % (5 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SGEN Stock Performance relative to its Competitors
SGEN Stock Performance relative to High-Confidence Competitors
SGEN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Jasper Therapeutics Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Century Therapeutics inc | 282.9% | Outperformed |
| 4 | Immunitybio inc | 282.9% | Outperformed |
| 5 | Revolution Medicines Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Seagen Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Seagen Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Seagen Inc |
43,034.00 | 2,300.35 |
 Astrazeneca Plc |
291,719.12 | 58,739.00 |
 Amgen Inc |
254,015.58 | 38,903.00 |
 Gilead Sciences Inc |
213,758.37 | 30,988.00 |
 Bristol myers Squibb Company |
128,928.40 | 50,033.00 |
 Argenx Se |
64,150.68 | 8,399.37 |
| SUBTOTAL | 1,199,232.43 | 211,503.96 |
Sign in to see all competitors of Seagen Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Seagen Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Seagen Inc's Competitors Named by the Company
Competitive relationships identified from Seagen Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicycle Therapeutics Plc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Artelo Biosciences Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Ocugen Inc | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Nexgel Inc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Cidara Therapeutics Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Aim Immunotech Inc | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Sanofi | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Takeda Pharmaceuticals | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Nanoviricides inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Agomab Therapeutics Nv | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Biontech Se | Company report | 85% |
| Novavax inc | Company report | 85% |
| Inhibrx Biosciences Inc | Company report | 85% |
| Verastem Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Cingulate Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Cardiff Oncology Inc | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Neonc Technologies Holdings Inc | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
| Valneva Se | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Heron Therapeutics Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Triple G | Company report | 85% |
| INVO | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Ladrx Corporation | Company report | 85% |
| 22nd Century Group inc | Company report | 85% |
| NAYA | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Curevac N v | Company report | 85% |
| Maravai Lifesciences Holdings Inc | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| ENTO | Company report | 85% |
| Larimar Therapeutics Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Acrotech Biopharma | Company report | 85% |
| Bioatla Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Theriva Biologics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Kyowa Kirin | Company report | 85% |
| Crinetics Pharmaceuticals Inc | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Avenir Wellness Solutions Inc | Company report | 85% |
| Celgene | Company report | 85% |
| Inflarx N V | Company report | 85% |
| SHOT | Company report | 85% |
| Bonk Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| BMS | Company report | 85% |
| Beyondspring Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Janssen Biotech | Company report | 85% |
| RENB | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Therapeuticsmd Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Dermata Therapeutics Inc | Company report | 85% |
| Protara Therapeutics Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Geovax Labs Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Relmada Therapeutics Inc | Company report | 85% |
| Vbi Vaccines Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Amphastar Pharmaceuticals Inc | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Matinas Biopharma Holdings Inc | Company report | 85% |
| Tenax Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Imunon Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Range Impact Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Cocrystal Pharma Inc | Company report | 85% |
| Evofem Biosciences Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Tonix Pharmaceuticals Holding Corp | Company report | 85% |
| Zyversa Therapeutics Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Biostax Corp | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Arcutis Biotherapeutics Inc | Company report | 85% |
| Curis Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Organon and Co | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Revolution Medicines Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Lianbio | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Arcturus Therapeutics Holdings Inc | Company report | 85% |
| Zymeworks Inc | Company report | 85% |
| Ionis Pharmaceuticals Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Roivant Sciences Ltd | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Sarepta Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Dr Reddy s Laboratories Limited | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Seagen Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Seagen Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Ligand Pharmaceuticals Incorporated | Development and Licensing of Biopharmaceutical Assets 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Seagen Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Seagen Inc | 43,034 | 1,916,959 | -625,187 |
| Astrazeneca Plc | 291,719 | 706,847 | 123,141 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Gilead Sciences Inc | 213,758 | 1,822,824 | -227,235 |
| Bristol myers Squibb Company | 128,928 | 1,539,477 | 284,338 |
| Argenx Se | 64,151 | 7,316,521 | 1,125,466 |
| PEERS TOTAL | 1,156,198 | 1,239,527 | 122,495 |
Seagen Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Bristol myers Squibb Company | United States 69.43 % |
| United Therapeutics Corporation | UNITED STATES 97.12 % |
| Exelixis Inc | United States 92.47 % |
| Immunitybio inc | United States 99.79 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Seagen Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 75.40 % | 35.09 % (avg) | +40.3 pp |
| Operating Margin | -34.37 % | industry median | +203.1 pp |
| EBITDA Margin | -28.94 % | -1.14 % (avg) | -27.8 pp |
| Capital Intensity (Capex / Revenue) | 7.00 % | 8.44 % (avg) | -1.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Seagen Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.6x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 14.1x | 5.3x | +8.8x |
| Return on Equity | -28.06 % | industry aggregate | -31.17 % |
| Return on Invested Capital | -14.78 % | -10.86 % (avg) | -3.92 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Seagen Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 17.45 % | 24.15 % | 15.33 % | 35.76 % | 40.02 % | 137.32 % | -27.63 % | 24.65 % |
| Operating Margin | -35.91 % | -34.13 % | -40.60 % | -39.71 % | -24.06 % | 27.43 % | -43.32 % | -31.24 % |
| Return on Invested Capital | -12.39 % | -10.28 % | -15.06 % | -9.76 % | -6.91 % | 12.52 % | -10.28 % | -10.53 % |
| P/E | - | - | - | - | - | 56.2x | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Seagen Inc's Strategic Group Map
Seagen Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Seagen Inc's trailing-12-month revenue growth of 23.4% and operating margin of -34.4% compares with an average of 21.0% growth and -23.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Seagen Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Seagen Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 7.00 % vs industry average 8.44 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Seagen Inc's dedicated Suppliers and Customers pages, not here.
Seagen Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Seagen Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Seagen Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 203.1 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+12.8% annualized vs trailing 12 months).
Weaknesses
- Return on equity 31.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (64.60 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-44.5% annualized).
Methodology: see Methodology: SWOT Analysis.
Seagen Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Seagen Inc | 0.43 | 3.22 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Argenx Se | 2.64 | 5.23 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Seagen Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Seagen Inc | Q3 2023 | +27.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| PEERS TOTAL | +12.9 % | +21.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Seagen Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Seagen Inc | Q3 2023 | +52.8 % | +175.7 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
Seagen Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Seagen Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Argenx Se | 14.88% | 14.81% | 17.64% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Seagen Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Seagen Inc | - | 18.71 |
| Astrazeneca Plc | 28.56 | 4.97 |
| Amgen Inc | 26.97 | 6.53 |
| Gilead Sciences Inc | - | 6.90 |
| Bristol myers Squibb Company | 13.92 | 2.58 |
| Argenx Se | 49.64 | 7.64 |
| PEERS AVERAGE | 60.19 | 5.67 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.